Clinical Trials Logo

Filter by:
NCT ID: NCT01844232 Completed - Multiple Sclerosis Clinical Trials

One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity

Start date: April 2013
Phase: Phase 3
Study type: Interventional

Clinical protocol OS440-3003 is a multicenter, open-label, non-randomized, uncontrolled, dose escalation study to evaluate the safety and tolerability of Arbaclofen Extended Release Tablets over 1 year in Multiple Sclerosis (MS) subjects with spasticity. All subjects in this study will receive arbaclofen in the extended release tablet formulation.

NCT ID: NCT01843842 Completed - Clinical trials for Acute Upper Respiratory Tract Infections

Clinical Trial of Safety and Clinical Efficacy of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Children

Start date: April 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is: - to assess safety of the liquid dosage form of Ergoferon for treatment of acute upper respiratory tract infections in children; - to assess clinical efficacy of the liquid dosage form of Ergoferon for treatment acute upper respiratory tract infections in children.

NCT ID: NCT01842607 Completed - Asthma Clinical Trials

A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects

Start date: May 27, 2013
Phase: Phase 3
Study type: Interventional

This is a multi-centre, open-label long-term safety study of 100 milligram (mg) mepolizumab administered subcutaneously (SC) every 4 weeks for 12 months in addition to standard of care in subjects who have severe, refractory asthma and a history of eosinophilic inflammation. Subjects who completed either MEA115588 or MEA115575 will be offered the opportunity to consent for this study.

NCT ID: NCT01842529 Completed - Clinical trials for Paroxysmal Atrial Fibrillation

Botulinum Toxin Injection in Epicardial Fat Pads To Treat Atrial Fibrillation After Cardiac Surgery

Start date: September 2012
Phase: Phase 2
Study type: Interventional

The aim of this prospective randomized double-blind study was to compare the efficacy and safety of Botulinum toxin injection in epicardial fat pads for preventing recurrences (in early postoperative period) of atrial tachyarrhythmia in patients with paroxysmal atrial fibrillation undergoing coronary artery bypass graft (CABG) surgery.

NCT ID: NCT01840410 Completed - Clinical trials for Choroidal Neovascularization (CNV)

Assess the Efficacy/Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Choroidal Neovascularization.

Start date: September 2013
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of 0.5 mg in adult patients with visual impairment due to choridal neovascularization (CNV).

NCT ID: NCT01839357 Completed - Atrial Fibrillation Clinical Trials

Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter

X-TRA
Start date: August 2013
Phase: Phase 3
Study type: Interventional

A study for subjects with atrial fibrillation (AF) or atrial flutter who are diagnosed with left atrial (LA) or left atrial appendage (LAA) thrombus. The study will assign subjects to rivaroxaban for treatment of thrombi. The study will measure thrombus outcomes based on echo image and common clinical outcomes such as bleeding and stroke or thromboembolism.

NCT ID: NCT01838681 Completed - Clinical trials for Major Depressive Disorder

Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

Start date: June 2013
Phase: Phase 3
Study type: Interventional

To evaluate the maintenance of efficacy and safety during long-term treatment with brexpiprazole as an adjunctive treatment for adult subjects with Major Depressive Disorder (MDD)

NCT ID: NCT01836523 Completed - Diabetes Clinical Trials

The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes

ADJUNCT ONEā„¢
Start date: November 2013
Phase: Phase 3
Study type: Interventional

This trial is conducted globally. The aim of the trial is to confirm the efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes. The total trial duration per subject is approximately 58 weeks.

NCT ID: NCT01835431 Completed - Diabetes Clinical Trials

A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus

Start date: October 17, 2013
Phase: Phase 3
Study type: Interventional

This trial is conducted in Asia, Europe and North and South America. The aim of the trial is to investigate the efficacy and safety of insulin degludec/insulin aspart once daily plus insulin aspart for the remaining meals in children and adolescents with type 1 diabetes mellitus.